Literature DB >> 12782675

The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis.

Geraldine Siegfried1, Ajoy Basak, James A Cromlish, Suzanne Benjannet, Jadwiga Marcinkiewicz, Michel Chrétien, Nabil G Seidah, Abdel-Majid Khatib.   

Abstract

The secretory factor VEGF-C has been directly implicated in various physiological processes during embryogenesis and human cancers. However, the importance of the conversion of its precursor proVEGF-C to mature VEGF-C in tumorigenesis, and vessel formation and the identity of the protease(s) that regulate these processes is/are not known. The intracellular processing of proVEGF-C that occurs within the dibasic motif HSIIRR(227)SL suggests the involvement of the proprotein convertases (PCs) in this process. In addition, furin and VEGF-C were found to be coordinately expressed in adult mouse tissues. Cotransfection of the furin-deficient colon carcinoma cell line LoVo with proVEGF-C and different PC members revealed that furin, PC5, and PC7 are candidate VEGF-C convertases. This finding is consistent with the in vitro digestions of an internally quenched synthetic fluorogenic peptide mimicking the cleavage site of proVEGF-C ((220)Q-VHSIIRR downward arrow SLP(230)). The processing of proVEGF-C is blocked by the inhibitory prosegments of furin, PC5, and PACE4, as well as by furin-motif variants of alpha2-macroglobulin and alpha1-antitrypsin. Subcutaneous injection of CHO cells stably expressing VEGF-C into nude mice enhanced angiogenesis and lymphangiogenesis, but not tumor growth. In contrast, expression of proVEGF-C obtained following mutation of the cleavage site (HSIIRR(227)SL to HSIISS(227)SL) inhibits angiogenesis and lymphangiogenesis as well as tumor growth. Our findings demonstrate the processing of proVEGF-C by PCs and highlight the potential use of PC inhibitors as agents for inhibiting malignancies induced by VEGF-C.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782675      PMCID: PMC156106          DOI: 10.1172/JCI17220

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In vitro and ex vivo assessment of their efficacy and selectivity.

Authors:  M Zhong; J S Munzer; A Basak; S Benjannet; S J Mowla; E Decroly; M Chrétien; N G Seidah
Journal:  J Biol Chem       Date:  1999-11-26       Impact factor: 5.157

2.  Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia.

Authors:  A Lymboussaki; B Olofsson; U Eriksson; K Alitalo
Journal:  Circ Res       Date:  1999-11-26       Impact factor: 17.367

3.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.

Authors:  M Jeltsch; A Kaipainen; V Joukov; X Meng; M Lakso; H Rauvala; M Swartz; D Fukumura; R K Jain; K Alitalo
Journal:  Science       Date:  1997-05-30       Impact factor: 47.728

4.  Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.

Authors:  J Lee; A Gray; J Yuan; S M Luoh; H Avraham; W I Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

5.  The developmental expression in rat of proteases furin, PC1, PC2, and carboxypeptidase E: implications for early maturation of proteolytic processing capacity.

Authors:  M Zheng; R D Streck; R E Scott; N G Seidah; J E Pintar
Journal:  J Neurosci       Date:  1994-08       Impact factor: 6.167

Review 6.  Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy.

Authors:  Abdel-Majid Khatib; Géraldine Siegfried; Michel Chrétien; Peter Metrakos; Nabil G Seidah
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

7.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

Authors:  A Kaipainen; J Korhonen; T Mustonen; V W van Hinsbergh; G H Fang; D Dumont; M Breitman; K Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

8.  Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics.

Authors:  A P Kyriazis; A A Kyriazis; D G Scarpelli; J Fogh; M S Rao; R Lepera
Journal:  Am J Pathol       Date:  1982-02       Impact factor: 4.307

9.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.

Authors:  V Joukov; K Pajusola; A Kaipainen; D Chilov; I Lahtinen; E Kukk; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1996-01-15       Impact factor: 11.598

10.  VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.

Authors:  E Kukk; A Lymboussaki; S Taira; A Kaipainen; M Jeltsch; V Joukov; K Alitalo
Journal:  Development       Date:  1996-12       Impact factor: 6.868

View more
  76 in total

1.  The proprotein convertase PC7: unique zymogen activation and trafficking pathways.

Authors:  Estelle Rousselet; Suzanne Benjannet; Josée Hamelin; Maryssa Canuel; Nabil G Seidah
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

2.  Rspo1/Wnt signaling promotes angiogenesis via Vegfc/Vegfr3.

Authors:  Aniket V Gore; Matthew R Swift; Young R Cha; Brigid Lo; Mary C McKinney; Wenling Li; Daniel Castranova; Andrew Davis; Yoh-suke Mukouyama; Brant M Weinstein
Journal:  Development       Date:  2011-10-17       Impact factor: 6.868

3.  When it comes to blocking lymphatics, it is all a question of time.

Authors:  M Luisa Iruela-Arispe
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

4.  Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation.

Authors:  Min Xu; Mb Majella Doyle; Babak Banan; Neeta Vachharajani; Xuanchuan Wang; Nael Saad; Kathryn Fowler; Elizabeth M Brunt; Yiing Lin; William C Chapman
Journal:  J Am Coll Surg       Date:  2017-04-09       Impact factor: 6.113

Review 5.  Processing of peptide and hormone precursors at the dibasic cleavage sites.

Authors:  Mohamed Rholam; Christine Fahy
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

Review 6.  Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer.

Authors:  A D Karatzanis; E Koudounarakis; I Papadakis; G Velegrakis
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-21       Impact factor: 2.503

7.  Regulation of HIF-1 alpha by the proprotein convertases furin and PC7 in human squamous carcinoma cells.

Authors:  Jian Fu; Jirong Zhang; Yulan Gong; Courtney Lyons Testa; Andres J Klein-Szanto
Journal:  Mol Carcinog       Date:  2014-01-16       Impact factor: 4.784

8.  E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironment.

Authors:  Tao Yang; Ingo Grafe; Yangjin Bae; Shan Chen; Yuqing Chen; Terry K Bertin; Ming-Ming Jiang; Catherine G Ambrose; Brendan Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

9.  Differential processing of neuropeptide proprotein in human breast adenocarcinoma.

Authors:  J H Zhang; D Zhou; J You; B S Tang; P Y Li; S S Tang
Journal:  J Endocrinol Invest       Date:  2013-04-12       Impact factor: 4.256

Review 10.  Role of subtilisin-like convertases in cadherin processing or the conundrum to stall cadherin function by convertase inhibitors in cancer therapy.

Authors:  E J Müller; R Caldelari; H Posthaus
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.